The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 05, 2022

Filed:

Jul. 29, 2020
Applicant:

Ionis Pharmaceuticals, Inc., Carlsbad, CA (US);

Inventors:

Susan M. Freier, San Diego, CA (US);

Chenguang Zhao, San Diego, CA (US);

Brett P. Monia, Encinitas, CA (US);

Hong Zhang, Fremont, CA (US);

Jeffrey R. Crosby, Carlsbad, CA (US);

Andrew M. Siwkowski, Carlsbad, CA (US);

Assignee:

Ionis Pharmaceuticals, Inc., Carlsbad, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/113 (2010.01); A61K 31/366 (2006.01); A61K 31/7125 (2006.01); C07H 21/00 (2006.01); A61K 31/4365 (2006.01); A61K 31/4545 (2006.01); A61K 31/713 (2006.01); A61K 31/737 (2006.01); A61K 31/727 (2006.01);
U.S. Cl.
CPC ...
A61K 31/7125 (2013.01); A61K 31/366 (2013.01); A61K 31/4365 (2013.01); A61K 31/4545 (2013.01); A61K 31/713 (2013.01); A61K 31/727 (2013.01); A61K 31/737 (2013.01); C07H 21/00 (2013.01); C12N 15/1137 (2013.01); C12Y 304/21027 (2013.01); C12N 2310/11 (2013.01); C12N 2310/315 (2013.01); C12N 2310/321 (2013.01); C12N 2310/3341 (2013.01); C12N 2310/341 (2013.01); C12N 2310/346 (2013.01);
Abstract

Disclosed herein are antisense compounds and methods for decreasing Factor 11 and treating or preventing thromboembolic complications in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to Factor 11 include thrombosis, embolism, and thromboembolism, such as, deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke. Antisense compounds targeting Factor 11 can also be used as a prophylactic treatment to prevent individuals at risk for thrombosis and embolism.


Find Patent Forward Citations

Loading…